Neumora Therapeutics, Inc. (NMRA) Monday said its Phase 1 study of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). The decision was followed by recently available pre-clinical data showing convulsions in rabbits.
Subsequently, the company paused its Phase 1 study, in which about 30 participants were dosed with NMRA-266. No evidence of convulsions was observed in any participant.
The company's shares were down more than 14 percent in pre-market on Monday to $10.20. The stock had closed at $13.56, down 3.21 percent on Friday. It has been trading in the range of $9.35 - $21.00 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.